Navigation Links
Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging

vely.
  • Tramiprosate (Alzhemed? crosses the blood-brain-barrier to exert its activity with low toxicity in various animal species that were tested.

    • The presence of amyloid in the brain is one of the major histopathological characteristics of AD. The amyloid cascade hypothesis proposes that certain forms of Aβ peptide are toxic and causally related to the severity of AD. The Aβ-peptide is one of the most promising targets for the development of AD therapies.

    "This scientific paper highlights the potential benefits of Alzhemed?" said Dr. Andreas Orfanos, Neurochem's Executive Vice President, Strategic Planning and Scientific Affairs. "These preclinical results indicate that AlzhemedTM binds preferentially to soluble amyloid β peptide, interferes with the amyloid cascade and reduces the associated toxicity. Accordingly, this product candidate is shown to impede key detrimental events normally associated with Alzheimer's disease and which are believed to lead to severe consequences in the brain of the affected individuals."

    About tramiprosate (Alzhemed?
    Tramiprosate (Alzhemed? is a small, orally-administered molecule known as an amyloid β antagonist, designed to cross the blood-brain-barrier, bind to soluble Aβ peptide and interfere with the amyloid cascade, thereby leading to the prevention or inhibition of amyloid deposition and the toxic effects of Aβ peptide in the brain.

    About the Phase III Clinical Trials for tramiprosate (Alzhemed?
    Neurochem is currently conducting a multi-center, randomized, double-blind, placebo-controlled and parallel-designed, 18-month Phase III clinical trial in 1,052 mild-to-moderate AD patients which is being carried out at close to 70 clinical sites across the United States and Canada. To date, 600 patients have already completed 12 months on study medication and the trial is scheduled to be completed by January 2007. All patients who complete the
    '"/>

    Source:Neurochem, Inc.


    Page: 1 2 3

    Related biology news :

    1. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
    2. Dual gene therapy suppresses lung cancer in preclinical test
    3. Gene vaccine for Alzheimers disease shows promising results
    4. Roche clinical trial registry and results database launched
    5. Diabetic nerve therapy shows striking results
    6. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
    7. New results validating Pall prion reduction filter disclosed at ISBT Congress
    8. Combination therapy shows promising results in patients with advanced lung cancer
    9. Vaccine for brain tumors shows promising results
    10. Artificial cornea offers better results for infants, some blind patients
    11. Encouraging results in pancreatic cancer research
    Post Your Comments: